Author:
Buechel Megan E.,Enserro Danielle,Burger Robert A.,Brady Mark F.,Wade Katrina,Secord Angeles Alvarez,Nixon Andrew B.,Mirniaharikandehei Seyedehnafiseh,Liu Hong,Zheng Bin,O'Malley David M.,Gray Heidi,Tewari Krishnansu S.,Mannel Robert S.,Birrer Michael J.,Moore Kathleen N.
Funder
National Cancer Institute
University of Oklahoma Stephenson Cancer Center
Subject
Obstetrics and Gynaecology,Oncology
Reference30 articles.
1. Cancer Facts and Figures 2019;American Cancer Society,2019
2. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer;Cooper;Clin. Cancer Res.,2002
3. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J. Clin. Oncol.,2012
4. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer;Aghajanian;Gynecol. Oncol.,2015
5. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献